Phi Pharma SA

Jantar GmbH is a small pharmaceutical R&D company in the field of chronic rhinosinusitis. It developed a nasal spray and provided clinical proof that it alleviates all symptoms of the disease.  A PCT patent has been filed. The identity of the active ingredient will be disclosed shortly.

Mabylon is leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Enantios is a Swiss startup revolutionizing molecular characterization with in-solution structural analysis of chiral complex molecules and Antibody drug Conjugates (ADCs). Enantios delivers solutions for quality control and drug development in pharmaceutical, biotech, and chemical industries.